Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Tirzepatide on Weight Loss and Inflammation in HIV
NCT06935838Phase 2Completed
- Sponsor
- University of Hawaiʻi
- Start
- Nov 2025
- Primary completion
- Jun 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirzepatide in obesity, sponsored by University of Hawaiʻi. Primary endpoint: Change in Baseline Body Weight at 12 weeks. Started Nov 2025; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06935838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06935838.